OVERSEA CHINESE BANKING Corp Ltd Boosts Stake in Moderna, Inc. (NASDAQ:MRNA)

OVERSEA CHINESE BANKING Corp Ltd raised its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 1,123.8% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,845 shares of the company’s stock after buying an additional 26,488 shares during the quarter. OVERSEA CHINESE BANKING Corp Ltd’s holdings in Moderna were worth $1,844,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in the company. GSA Capital Partners LLP purchased a new position in shares of Moderna in the 3rd quarter worth $377,000. Entropy Technologies LP purchased a new position in Moderna in the third quarter worth about $778,000. Apollon Wealth Management LLC increased its stake in Moderna by 23.5% during the third quarter. Apollon Wealth Management LLC now owns 5,064 shares of the company’s stock worth $338,000 after acquiring an additional 962 shares during the last quarter. Intrinsic Value Partners LLC raised its position in Moderna by 91.1% during the third quarter. Intrinsic Value Partners LLC now owns 51,392 shares of the company’s stock valued at $3,435,000 after purchasing an additional 24,505 shares during the period. Finally, Privium Fund Management B.V. lifted its stake in shares of Moderna by 74.0% in the 3rd quarter. Privium Fund Management B.V. now owns 40,482 shares of the company’s stock valued at $2,705,000 after purchasing an additional 17,221 shares during the last quarter. Institutional investors own 75.33% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on MRNA shares. Bank of America cut their target price on Moderna from $130.00 to $110.00 and set a “neutral” rating on the stock in a research report on Friday, September 13th. The Goldman Sachs Group reduced their target price on shares of Moderna from $178.00 to $139.00 and set a “buy” rating on the stock in a research note on Monday, September 16th. Deutsche Bank Aktiengesellschaft upgraded shares of Moderna from a “sell” rating to a “hold” rating and lowered their target price for the stock from $85.00 to $80.00 in a report on Wednesday, August 7th. Jefferies Financial Group cut their price target on shares of Moderna from $65.00 to $55.00 and set a “hold” rating on the stock in a report on Tuesday, October 15th. Finally, UBS Group decreased their price objective on shares of Moderna from $140.00 to $108.00 and set a “buy” rating for the company in a research note on Thursday, October 24th. Two investment analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $93.18.

Insider Activity

In related news, CFO James M. Mock sold 715 shares of the business’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $60.12, for a total value of $42,985.80. Following the completion of the transaction, the chief financial officer now owns 9,505 shares of the company’s stock, valued at $571,440.60. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other Moderna news, CFO James M. Mock sold 715 shares of Moderna stock in a transaction dated Monday, October 7th. The stock was sold at an average price of $60.12, for a total value of $42,985.80. Following the transaction, the chief financial officer now owns 9,505 shares in the company, valued at $571,440.60. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James M. Mock sold 1,321 shares of the business’s stock in a transaction dated Wednesday, August 28th. The stock was sold at an average price of $79.39, for a total transaction of $104,874.19. Following the completion of the transaction, the chief financial officer now owns 8,600 shares of the company’s stock, valued at $682,754. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 2,930 shares of company stock worth $217,170. Corporate insiders own 15.20% of the company’s stock.

Moderna Stock Up 1.7 %

Shares of MRNA stock opened at $43.47 on Wednesday. Moderna, Inc. has a twelve month low of $41.54 and a twelve month high of $170.47. The company has a current ratio of 4.39, a quick ratio of 4.20 and a debt-to-equity ratio of 0.05. The stock has a fifty day simple moving average of $61.15 and a two-hundred day simple moving average of $98.65.

Moderna (NASDAQ:MRNA) last released its quarterly earnings data on Thursday, November 7th. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.89) by $1.92. The company had revenue of $1.90 billion during the quarter, compared to analyst estimates of $1.25 billion. Moderna had a negative net margin of 43.77% and a negative return on equity of 17.68%. The firm’s revenue for the quarter was up 3.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($1.39) earnings per share. On average, research analysts expect that Moderna, Inc. will post -9.39 EPS for the current year.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.